- Home
- NBIS vs MDGL Comparison
NBIS vs MDGL Comparison
Compare NBIS & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIS
- MDGL
- Stock Information
- Founded
- NBIS N/A
- MDGL 2011
- Country
- NBIS
- MDGL United States
- Employees
- NBIS 26361
- MDGL N/A
- Industry
- NBIS
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- NBIS
- MDGL Health Care
- Exchange
- NBIS NYSE
- MDGL Nasdaq
- Market Cap
- NBIS 6.5B
- MDGL 7.4B
- IPO Year
- NBIS N/A
- MDGL N/A
- Fundamental
- Price
- NBIS $29.00
- MDGL $306.23
- Analyst Decision
- NBIS
- MDGL Buy
- Analyst Count
- NBIS 0
- MDGL 14
- Target Price
- NBIS N/A
- MDGL $347.33
- AVG Volume (30 Days)
- NBIS N/A
- MDGL 319.4K
- Earning Date
- NBIS N/A
- MDGL 10-31-2024
- Dividend Yield
- NBIS N/A
- MDGL N/A
- EPS Growth
- NBIS N/A
- MDGL N/A
- EPS
- NBIS N/A
- MDGL N/A
- Revenue
- NBIS N/A
- MDGL $76,813,000.00
- Revenue This Year
- NBIS N/A
- MDGL N/A
- Revenue Next Year
- NBIS N/A
- MDGL $194.49
- P/E Ratio
- NBIS N/A
- MDGL N/A
- Revenue Growth
- NBIS N/A
- MDGL N/A
- 52 Week Low
- NBIS N/A
- MDGL $168.25
- 52 Week High
- NBIS N/A
- MDGL $368.29
- Technical
- Relative Strength Index (RSI)
- NBIS N/A
- MDGL 49.18
- Support Level
- NBIS N/A
- MDGL $295.02
- Resistance Level
- NBIS N/A
- MDGL $315.09
- Average True Range (ATR)
- NBIS 0.00
- MDGL 10.62
- MACD
- NBIS 0.00
- MDGL -4.31
- Stochastic Oscillator
- NBIS 0.00
- MDGL 32.63
About NBIS NEBIUS GROUP N V
Nebius Group NV is a tech company. It is a European provider of infrastructure and services to AI builders globally. The group builds full-stack infrastructure to service the growth of the AI industry, including the scale of GPU clusters, cloud platforms, tools, and services for developers. It has R&D hubs across Europe, North America and Israel.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.